HC Wainwright Expects Lower Earnings for Coya Therapeutics

Coya Therapeutics, Inc. (NASDAQ:COYA – Free Report) – Analysts at HC Wainwright reduced their FY2026 earnings estimates for shares of Coya Therapeutics in a research note issued to investors on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($1.50) per share for the year, down from their prior estimate of ($1.30). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.53) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q4 2026 earnings at ($0.45) EPS and Q4 2027 earnings at ($0.34) EPS.

A number of other research analysts also recently issued reports on COYA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Thursday, October 15th. Roth Capital restated a “buy” rating and issued a $12.00 target price on shares of Coya Therapeutics in a research note on Monday, August 24th. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Wednesday, August 12th. Wall Street Zen downgraded Coya Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, BTIG Research reaffirmed a “buy” rating and set a $16.00 price target on shares of Coya Therapeutics in a research note on Tuesday, September 15th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Check Out Our Latest Stock Analysis on COYA

Coya Therapeutics Price Performance

Shares of Coya Therapeutics stock opened at $3.02 on Monday. The firm has a market cap of $70.85 million, a price-to-earnings ratio of -2.17 and a beta of 0.70. The stock’s 50-day moving average is $4.23 and its 200-day moving average is $4.56. Coya Therapeutics has a one year low of $2.72 and a one year high of $6.62.

Coya Therapeutics (NASDAQ:COYA – Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.11). Coya Therapeutics had a negative return on equity of 71.48% and a negative net margin of 643.44%. The firm had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.11 million.

Institutional Trading of Coya Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of COYA. Cetera Investment Advisers lifted its stake in Coya Therapeutics by 36.4% in the first quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock valued at $118,000 after acquiring an additional 8,000 shares during the last quarter. Allworth Financial LP grew its position in shares of Coya Therapeutics by 1,200.0% in the 2nd quarter. Allworth Financial LP now owns 13,000 shares of the company’s stock valued at $76,000 after acquiring an additional 12,000 shares during the period. AXQ Capital LP bought a new position in shares of Coya Therapeutics in the 2nd quarter valued at about $116,000. Goldman Sachs Group Inc. increased its stake in shares of Coya Therapeutics by 77.3% during the 3rd quarter. Goldman Sachs Group Inc. now owns 46,421 shares of the company’s stock worth $233,000 after purchasing an additional 20,241 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Coya Therapeutics by 55.4% during the 1st quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock worth $410,000 after purchasing an additional 37,064 shares during the last quarter. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

(Get Free Report)

Coya Therapeutics is a clinical-stage biotechnology company developing therapies that aim to enhance the function of regulatory T cells, immune cells that help control inflammation. Its research focuses on potential treatments for neurodegenerative and other diseases associated with inflammation and immune dysfunction. The company’s development programs include biologic and cell-based approaches, with candidates under investigation for conditions including amyotrophic lateral sclerosis (ALS). These therapies remain in development; Coya does not have an approved commercial product.

Read More

Earnings History and Estimates for Coya Therapeutics (NASDAQ:COYA)

Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.